Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
April 6th, 2024
Publishment of data from our pipelineat the American Association for Cancer Research Annual Meeting 2024
Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the researchand development of novel therapies for cancer, presented new data at the American
Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San
Diego, California.
Regarding CTX-712, CLK inhibitor, a total of 46 patients with solid tumors and a
total of 14 patients with hematologic malignancies were enrolled in the CTX-712-CL01 study to evaluate the safety, pharmacokinetics (PK) / pharmacodynamics (PD)profile and preliminary efficacy as of data cutoff on November 20, 2023. Observed
DLTs (Dose-limited Toxicity) were dehydration, platelet count decrease, andhypokalemia, and MTD (Maximum Tolerated Dose) was determined to be 140mg
twice a week. Common any-grade-related adverse events were nausea and vomiting.
Among all patients, partial responses were observed in 4 patients (4/46, 8.6%), whowere all patients with ovarian cancers. (4/14, 28.6%). Among a total of AML and MDS
patients (14), CR(Complete Remission) was observed in 3 patients, CRi (CompleteRemission without incomplete hematologic recovery) was observed in 1 patient andMLFS (Morphologic Leukemia-Free State) was observed in 1 patient, so overallresponse rate is 42.9%. In PK analysis, a dose-dependent increase in systemic
exposure of CTX-712 was overserved, and a dose-dependent increase of exon skippingin two maker RNAs that are extracted from peripheral blood cell demonstrated PD
effect induced by CTX-712.
Regarding CTX-439, CDK12 inhibitor, we reported (1) pharmacodynamics (PD)markers to monitor the suppression of CDK12/13 in humans, (2) patient selection
biomarkers to determine sensitivity to CTX-439, and a significant anti-tumor effect
was revealed in PDX models that showed sensitivity in the survey, (3) a synergistic
effect in combination with PARP inhibitors and other chemotherapy and moleculartargeted drugs. in vitro and in vivo.
Regarding GCN2, we reported that our candidate compound inhibiting theHRI/PERK/GCN2 triple kinase in cells observed a distinct anti-growth effect forMultiple Myeloma with resistant to proteasome inhibitors when combined withproteasome inhibitors in vitro and in vivo.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com<Overview of presentation at AACR 2024>
Presentation on CTX-712, CLK inhibitor

Abstract No
Title

CT115
A first-in-human phase I study of CTX-712 in patients withadvanced, relapsed or refractory malignant tumors (CTX-712-CL01 study): Efficacy and safety in a hematologic malignancies
cohortAbstract No
Title

CT110
A first-in-human phase I study of CTX-712 in patients withadvanced, relapsed or refractory malignant tumors (CTX-712-CL01 study): Efficacy and safety in solid tumor cohorts

Abstract NoTitle

2081
Biomarkers for CLK inhibitor CTX-712 treatment response inmyeloid neoplasms: Paving the way toward clinical trials

Presentation on CTX-439, CDK12 inhibitor

Abstract NoTitle

3301
Translational Research of CDK12/13 Inhibitor, CTX-439,
Informing Clinical Trial Strategy

Presentation on GCN2 inhibitor

Abstract NoTitle

1233
Novel inhibitor targeting triple integrated stress response kinase
HRI, PERK, and GCN2 provides new insights into overcoming
resistance to proteasome inhibitors in multiple myeloma

About CTX-712
CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor ofCDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays animportant role in cell growth. For more information, please visit: jRCT2080224127 fordetails on the Japan phase 1 clinical trial and clinicaltrials.gov/ (NCT05732103) for
details on the US Phase 1/2 clinical trial of CTX-712.
About Chordia Therapeutics
Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture,
Japan, is developing novel cancer therapies. Chordia’s lead asset, CLK inhibitor CTX712, is currently in Phase 1 clinical study in Japan and Phase1/2 clinical study in theUS. CTX-712 potentially targets vulnerabilities in cancer and could benefits patientswith various types of cancer. In addition to CTX-712, Chordia is researching several
preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective
in cancers with specific abnormalities, as well as GCN2 inhibitors.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, please contact Mizobe in IR: ir@chordiatherapeutics.com